<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, June 4, 2018 (HealthDay News) — The oxaliplatin, leucovorin, irinotecan, and 5-fluorouracil (mFOLFIRINOX) regimen is associated with longer median disease-free and overall survival in pancreatic ductal adenocarcinoma; and, receiving chemotherapy before surgery is associated with better disease-free survival, according to two studies presented at the annual meeting of the American Society of Clinical Oncology, held from June 1 to 5 in Chicago.<\/p>\n
Thierry Conroy, M.D., from the Institut de Canc\u00e9rologie de Lorraine in Vand\u009cuvre-l\u00e8s-Nancy, France, and colleagues randomized patients with histologically proven pancreatic ductal adenocarcinomas, 21 to 84 days after resection, to six cycles of gemcitabine (arm A; 246 patients) or 12 cycles of mFOLFIRINOX (arm B; 247 patients). The researchers found that the median disease-free survival was 12.8 and 21.6 months in arms A and B, respectively, with a median follow-up of 30.5 months (hazard ratio, 0.59). The median overall survival was 34.8 and 54.4 months in arms A and B, respectively (hazard ratio, 0.66).<\/p>\n
Geertjan van Tienhoven, M.D., Ph.D., from the Academic Medical Center in Amsterdam, and colleagues randomized patients with (borderline) resectable pancreatic cancer to immediate surgery (arm A; 127 patients) and preoperative chemoradiotherapy (arm B; 119 patients). The researchers found that overall survival was significantly better with preoperative chemoradiotherapy (median, 13.5 versus 17.1 months; hazard ratio, 0.71; P = 0.047). Disease-free survival was also significantly better in arm B (median, 7.9 versus 11.2 months; hazard ratio, 0.67; P = 0.010).<\/p>\n
“This is the first randomized clinical trial to show that preoperative treatment improves outcomes for people with early stages of pancreatic cancer who can have surgery,” van Tienhoven said in a statement.<\/p>\n
Press Release – Conroy<\/a><\/p>\n Press Release – van Tienhoven<\/a><\/p>\n